16
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19

      research-article
      , MD, PhD a , b , , MD a , , MD a , , MD a , , MD a , , MD, PhD b , , MD a , , MD, MSc a , , MD, MHSc a , , MSc a , , PhD a , , PhD c , d , e , , MD d , f , g , i , , MD c , e , j , k , , PhD l , m , , MD, PhD a , n , , MD a , , MD a , h ,
      Journal of the American College of Cardiology
      by the American College of Cardiology Foundation. Published by Elsevier.
      coronavirus, COVID-19, heart failure, left ventricular ejection fraction, outcome, renin-angiotensin-aldosterone system inhibitor, AdjOR, adjusted odds ratio, CI, confidence interval, COVID-19, coronavirus disease-2019, HF, heart failure, HFpEF, heart failure with preserved ejection fraction, HFmrEF, heart failure with mid-range ejection fraction, HFrEF, heart failure with reduced ejection fraction, ICD, International Classification of Disease, ICU, intensive care unit, IQR, interquartile range, LOS, length of stay, LVEF, left ventricular ejection fraction, RAASi, renin-angiotensin-aldosterone inhibitor, SARS-CoV-2, severe acute respiratory syndrome- coronavirus-2

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Patients with pre-existing heart failure (HF) are likely at higher risk for adverse outcomes in coronavirus disease-2019 (COVID-19), but data on this population are sparse.

          Objectives

          This study described the clinical profile and associated outcomes among patients with HF hospitalized with COVID-19.

          Methods

          This study conducted a retrospective analysis of 6,439 patients admitted for COVID-19 at 1 of 5 Mount Sinai Health System hospitals in New York City between February 27 and June 26, 2020. Clinical characteristics and outcomes (length of stay, need for intensive care unit, mechanical ventilation, and in-hospital mortality) were captured from electronic health records. For patients identified as having a history of HF by International Classification of Diseases-9th and/or 10th Revisions codes, manual chart abstraction informed etiology, functional class, and left ventricular ejection fraction (LVEF).

          Results

          Mean age was 63.5 years, and 45% were women. Compared with patients without HF, those with previous HF experienced longer length of stay (8 days vs. 6 days; p < 0.001), increased risk of mechanical ventilation (22.8% vs. 11.9%; adjusted odds ratio: 3.64; 95% confidence interval: 2.56 to 5.16; p < 0.001), and mortality (40.0% vs. 24.9%; adjusted odds ratio: 1.88; 95% confidence interval: 1.27 to 2.78; p = 0.002). Outcomes among patients with HF were similar, regardless of LVEF or renin-angiotensin-aldosterone inhibitor use.

          Conclusions

          History of HF was associated with higher risk of mechanical ventilation and mortality among patients hospitalized for COVID-19, regardless of LVEF.

          Central Illustration

          Related collections

          Most cited references39

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

          Summary Background A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of these patients. Methods All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan. We prospectively collected and analysed data on patients with laboratory-confirmed 2019-nCoV infection by real-time RT-PCR and next-generation sequencing. Data were obtained with standardised data collection forms shared by WHO and the International Severe Acute Respiratory and Emerging Infection Consortium from electronic medical records. Researchers also directly communicated with patients or their families to ascertain epidemiological and symptom data. Outcomes were also compared between patients who had been admitted to the intensive care unit (ICU) and those who had not. Findings By Jan 2, 2020, 41 admitted hospital patients had been identified as having laboratory-confirmed 2019-nCoV infection. Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]). Median age was 49·0 years (IQR 41·0–58·0). 27 (66%) of 41 patients had been exposed to Huanan seafood market. One family cluster was found. Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38). Dyspnoea developed in 22 (55%) of 40 patients (median time from illness onset to dyspnoea 8·0 days [IQR 5·0–13·0]). 26 (63%) of 41 patients had lymphopenia. All 41 patients had pneumonia with abnormal findings on chest CT. Complications included acute respiratory distress syndrome (12 [29%]), RNAaemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%]). 13 (32%) patients were admitted to an ICU and six (15%) died. Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFα. Interpretation The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. Major gaps in our knowledge of the origin, epidemiology, duration of human transmission, and clinical spectrum of disease need fulfilment by future studies. Funding Ministry of Science and Technology, Chinese Academy of Medical Sciences, National Natural Science Foundation of China, and Beijing Municipal Science and Technology Commission.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China

            In December 2019, novel coronavirus (2019-nCoV)-infected pneumonia (NCIP) occurred in Wuhan, China. The number of cases has increased rapidly but information on the clinical characteristics of affected patients is limited.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

              Summary The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.
                Bookmark

                Author and article information

                Journal
                J Am Coll Cardiol
                J Am Coll Cardiol
                Journal of the American College of Cardiology
                by the American College of Cardiology Foundation. Published by Elsevier.
                0735-1097
                1558-3597
                28 October 2020
                28 October 2020
                Affiliations
                [a ]The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York
                [b ]Cardiology Department, Hospital de la Santa Creu i Sant Pau, IIb-SantPau, CIBERCV, Universitat Autónoma de Barcelona, Barcelona, Spain
                [c ]The Hasso Plattner Institute for Digital Health at Mount Sinai, New York, New York
                [d ]Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York
                [e ]The Mount Sinai Clinical Intelligence Center, New York, New York
                [f ]Institute for Healthcare Delivery Science, Icahn School of Medicine at Mount Sinai, New York, New York
                [g ]Department of Anesthesiology, Perioperative and Pain Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
                [h ]Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York
                [i ]Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, New York
                [j ]Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
                [k ]Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
                [l ]The BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
                [m ]Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York
                [n ]Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain
                Author notes
                [] Address for correspondence: Dr. Anuradha Lala, The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, Box 1030, New York, New York 10029.
                Article
                S0735-1097(20)37242-9
                10.1016/j.jacc.2020.09.549
                7598769
                33129663
                279ef094-23d5-4138-bbac-f8e26e45a0fd
                © 2020 by the American College of Cardiology Foundation. Published by Elsevier.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 5 August 2020
                : 14 September 2020
                : 17 September 2020
                Categories
                Original Investigation

                Cardiovascular Medicine
                coronavirus,covid-19,heart failure,left ventricular ejection fraction,outcome,renin-angiotensin-aldosterone system inhibitor,adjor, adjusted odds ratio,ci, confidence interval,covid-19, coronavirus disease-2019,hf, heart failure,hfpef, heart failure with preserved ejection fraction,hfmref, heart failure with mid-range ejection fraction,hfref, heart failure with reduced ejection fraction,icd, international classification of disease,icu, intensive care unit,iqr, interquartile range,los, length of stay,lvef, left ventricular ejection fraction,raasi, renin-angiotensin-aldosterone inhibitor,sars-cov-2, severe acute respiratory syndrome- coronavirus-2

                Comments

                Comment on this article